3D-pharmacophore identification for κ-opioid agonists using ligand-based drug-design techniques

Topics in Current Chemistry

Volumn 299, Issue , 2011, Pages 277-307

  Yamaotsu, Noriyuki ^a   Hirono, Shuichi ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

Agonist; k Opioid receptor; Molecular superposition; Pharmacophore; Selectivity

Indexed keywords

KAPPA OPIATE RECEPTOR; LIGAND;

ARTICLE; CHEMICAL STRUCTURE; DRUG DESIGN; DRUG POTENTIATION; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING;

DRUG DESIGN; IMAGING, THREE-DIMENSIONAL; LIGANDS; MODELS, MOLECULAR; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79551504693     PISSN: 03401022     EISSN: None     Source Type: Book Series    
DOI: 10.1007/128_2010_84     Document Type: Article

References (74)

1. Kieffer BL (1995) Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol 15:615-635
2. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M (1996) International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol Rev 48:567-592
3. Millan MJ (1990) k-Opioid receptors and analgesia. Trends Pharmacol Sci 11:70-76
4. Williams M, Kowaluk EA, Arneric SP (1999) Emerging molecular approaches to pain therapy. J Med Chem 42:1481-1500
5. Chavkin C, Goldstein A (1981) Specific receptor for the opioid peptide dynorphin: structure- activity relationships. Proc Natl Acad Sci USA 78:6543-6547
6. Dooley CT, Ny P, Bidlack JM, Houghten RA (1998) Selective ligands for the m, d, and k opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library. J Biol Chem 273:18848-18856
7. Przydzial MJ, Pogozheva ID, Bosse KE, Andrews SM, Tharp TA, Traynor JR, Mosberg HI (2005) Roles of residues 3 and 4 in cyclic tetrapeptide ligand recognition by the k-opioid receptor. J Pept Res 65:333-342
8. Houghten RA, Dooley CT, Appel JR (2006) In vitro and direct in vivo testing of mixture-based combinatorial libraries for the identification of highly active and specific opiate ligands. AAPS J 8:E371-E382
9. Corbett AD, Kosterlitz HW (1986) Bremazocine is an agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors in the guinea-pig myenteric plexus. Br J Pharmacol 89:245-249
10. Tamura T, Ogawa J, Taniguchi T, Waki I (1990) Preferential action of eptazocine, a novel analgesic, with opioid receptors in isolated guinea pig ileum and mouse vas deferens preparations. Folia Pharmacol Japon 95:41-46
11. Ronsisvalle G, Pasquinucci L, Pappalardo MS, Vittorio F, Fronza G, Romagnoli C, Pistacchio E, Spampinato S, Ferri S (1993) Non-peptide ligands for opioid receptors. Design of k-specific agonists. J Med Chem 36:1860-1865
12. Dortch-Carnes J, Potter DE (2005) Bremazocine: a k-opioid agonist with potent analgesic and other pharmacologic properties. CNS Drug Rev 11:195-212
13. Pasquinucci L, Iadanza M, Marrazzo A, Prezzavento O, Ronsisvalle S, Scoto GM, Parenti C, De Luca L, Ronsisvalle G (2007) New benzomorphan derivatives of MPCB as MOP and KOP receptor ligands. Pharmazie 62:813-824
14. Kawai K, Hayakawa J, Miyamoto T, Imamura Y, Yamane S, Wakita H, Fujii H, Kawamura K, Matsuura H, Izumimoto N, Kobayashi R, Endo T, Nagase H (2008) Design, synthesis, and structure-activity relationship of novel opioid k-agonists. Bioorg Med Chem 16:9188-9201
15. Nemoto T, Fujii H, Narita M, Miyoshi K, Nakamura A, Suzuki T, Nagase H (2008) Synthesis of a novel 6,14-epoxymorphinan derivative and its pharmacology. Bioorg Med Chem Lett 18:6398-6401
16. Nagase H, Watanabe A, Nemoto T, Yamaotsu N, Hayashida K, Nakajima M, Hasebe K, Nakao K, Mochizuki H, Hirono S, Fujii H (2010) Drug design and synthesis of a novel k opioid receptor agonist with an oxabicyclo[2.2.2]octane skeleton and its pharmacology. Bioorg Med Chem Lett 20:121-124
17. Szmuszkovicz J, Von Voigtlander PF (1982) Benzeneacetamide amines: structurally novel non-mm opioids. J Med Chem 25:1125-1126
18. Lahti RA, Mickelson MM, McCall JM, Von Voigtlander PF (1985) [3H]U-69593 a highly selective ligand for the opioid k receptor. Eur J Pharmacol 109:281-284
19. Halfpenny PR, Horwell DC, Hughes J, Hunter JC, Rees DC (1990) Highly selective k-opioid analgesics. 3. Synthesis and structure-activity relationships of novel N-[2-(1-pyrrolidinyl)-4-or -5-substituted cyclohexyl]arylacetamide derivatives. J Med Chem 33:286-291
20. Hunter JC, Leighton GE, Meecham KG, Boyle SJ, Horwell DC, Rees DC, Hughes J (1990) CI-977, a novel and selective agonist for the kappa-opioid receptor. Br J Pharmacol 101:183-189
21. Rajagopalan P, Scribner RM, Pennev P, Schmidt WK, Tam SW, Steinfels GF, Cook L (1992) DuP 747: a new, potent, kappa opioid analgesic. Synthesis and pharmacology1. Bioorg Med Chem Lett 2:715-720
22. Rajagopalan P, Scribner RM, Pennev P, Mattei PL, Kezar HS, Cheng CY, Cheeseman RS, Ganti VR, Johnson AL, Wuonola MA, Schmidt WK, Tam SW, Steinfels GF, Cook L (1992) DuP 747: sar study. Bioorg Med Chem Lett 2:721-726
23. Kögel B, Christoph T, Friderichs E, Hennies H-H, Matthiesen T, Schneider J, Holzgrabe U (1998) HZ2, a selective kappa-opioid agonist. CNS Drug Rev 4:54-70
24. Siener T, Cambareri A, Kuhl U, Englberger W, Haurand M, Kögel B, Holzgrabe U (2000) Synthesis and opioid receptor affinity of a series of 2,4-diaryl-substituted 3,7-diazabicylono-nanones. J Med Chem 43:3746-3751
25. Benyhe S, Márki A, Nachtsheim C, Holzgrabe U, Borsodi A (2003) Kappa-receptor selective binding of opioid ligands with a heterocyclic bicyclo[3.3.1]nonan-9-one structure. Acta Biol Hung 54:147-155
26. Houghten RA, Pinilla C, Appel JR, Blondelle SE, Dooley CT, Eichler J, Nefzi A, Ostresh JM (1999) Mixture-based synthetic combinatorial libraries. J Med Chem 42:3743-3778
27. Houghten RA, Pinilla C, Giulianotti MA, Appel JR, Dooley CT, Nefzi A, Ostresh JM, Yu Y, Maggiora GM, Medina-Franco JL, Brunner D, Schneider J (2008) Strategies for the use of mixture-based synthetic combinatorial libraries: scaffold ranking, direct testing in vivo, and enhanced deconvolution by computational methods. J Comb Chem 10:3-19
28. Freye E, Boeck G, Schaal M, Ciaramelli F (1986) The benzodiazepine (+)-tifluadom (KC-6128), but not its optical isomer (KC-5911) induces opioid kappa receptor-related EEG power spectra and evoked potential changes. Pharmacology 33:241-248
29. Cappelli A, Anzini M, Vomero S, Menziani MC, De Benedetti PG, Sbacchi M, Clarke GD, Mennuni L (1996) Synthesis, biological evaluation, and quantitative receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as novel tifluadom-like ligands with high affinity and selectivity for k-opioid receptors. J Med Chem 39:860-872
30. Azzolina O, Collina S, Linati L, Anzini M, Cappelli A, Scheideler MA, Sbacchi M (2001) Enantiomers of 2-[(acylamino)ethyl]-1,4-benzodiazepines, potent ligands of k-opioid receptor: chiral chromatographic resolution, configurational assignment, and biological activity. Chirality 13:606-612
31. Anzini M, Canullo L, Braile C, Cappelli A, Gallelli A, Vomero S, Menziani MC, De Benedetti PG, Rizzo M, Collina S, Azzolina O, Sbacchi M, Ghelardini C, Galeotti N (2003) Synthesis, biological evaluation, and receptor docking simulations of 2-[(acylamino)ethyl]-1,4-benzodiazepines as k-opioid receptor agonists endowed with antinociceptive and anti-amnesic activity. J Med Chem 46:3853-3864
32. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous k opioid selective agonist. Proc Natl Acad Sci USA 99:11934-11939
33. Yan F, Mosier PD, Westkaemper RB, Stewart J, Zjawiony JK, Vortherms TA, Sheffler DJ, Roth BL (2005) Identification of the molecular mechanisms by which the diterpenoid salvi-norin A binds to k-opioid receptors. Biochemistry 44:8643-8651
34. Kane BE, Nieto MJ, McCurdy CR, Ferguson DM (2006) A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist. FEBS J 273:1966-1974
35. Kane BE, McCurdy CR, Ferguson DM (2008) Toward a structure-based model of salvinorin A recognition of the k-opioid receptor. J Med Chem 51:1824-1830
36. Lavecchia A, Greco G, Novellino E, Vittorio F, Ronsisvalle G (2000) Modeling of k-opioid receptor/agonists interactions using pharmacophore-based and docking simulations. J Med Chem 43:2124-2134
37. Filizola M, Villar HO, Loew GH (2001) Molecular determinants of non-specific recognition of d, m, and k opioid receptors. Bioorg Med Chem 9:69-76
38. Filizola M, Villar HO, Loew GH (2001) Differentiation of d, m, and k opioid receptor agonists based on pharmacophore development and computed physicochemical properties. J Comput Aided Mol Des 15:297-307
39. Subramanian G, Paterlini MG, Larson DL, Portoghese PS, Ferguson DM (1998) Conforma-tional analysis and automated receptor docking of selective arylacetamide-based k-opioid agonists. J Med Chem 41:4777-4789
40. Holzgrabe U, Brandt W (2003) Mechanism of action of the diazabicyclononanone-type k-agonists. J Med Chem 46:1383-1389
41. Pogozheva ID, Przydzial MJ, Mosberg HI (2005) Homology modeling of opioid receptor-ligand complexes using experimental constraints. AAPS J 07:E434-E448
42. Kane BE, Svensson B, Ferguson DM (2006) Molecular recognition of opioid receptor ligands. AAPS J 8:E126-E137
43. Kolb P, Ferreira RS, Irwin JJ, Shoichet BK (2009) Docking and chemoinformatic screens for new ligands and targets. Curr Opin Biotechnol 20:429-436
44. Michino M, Brooks CL III (2009) Predicting structurally conserved contacts for homologous proteins using sequence conservation filters. Proteins 77:448-453
45. Michino M, Abola E, GPCR Dock 2008 participants, Brooks CL III, Dixon JS, Moult J, Stevens RC (2009) Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat Rev Drug Discov 8:455-463
46. De Graaf C, Rognan D (2009) Customizing G protein-coupled receptor models for structure-based virtual screening. Curr Pharm Des 15:4026-4048
47. Katritch V, Rueda M, Lam PC-H, Yeager M, Abagyan R (2010) GPCR 3D homology models for ligand screening: lessons learned from blind predictions of adenosine A2a receptor complex. Proteins 78:197-211
48. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, Reisine T (1994) Pharmacological characterization of the cloned k-, d-, and m-opioid receptors. Mol Pharmacol 45:330-334
49. Lapalu S, Moisand C, Mazarguil H, Cambois G, Mollereau C, Meunier J-C (1997) Comparison of the structure-activity relationships of nociceptin and dynorphin A using chimeric peptides. FEBS Lett 417:333-336
50. Emmerson PJ, Liu MR, Woods JH, Medzihradsky F (1994) Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630-1637
51. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH, Levine JD (1999) The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. Pain 83:339-345
52. Giardina G, Clarke GD, Dondio G, Petrone G, Sbacchi M, Vecchietti V (1994) Selective k-opioid agonists: synthesis and structure-activity relationships of piperidines incorporating an oxo-containing acyl group. J Med Chem 37:3482-3491
53. Wang Y, Tang K, Inan S, Siebert D, Holzgrabe U, Lee DYW, Huang P, Li J-G, Cowan A, Liu-Chen L-Y (2005) Comparison of pharmacological activities of three distinct k ligands(Salvinorin A, TRK-820 and 3FLB) on k opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther 312:220-230
54. Ostresh JM, Schoner CC, Hamashin VT, Nefzi A, Meyer J-P, Houghten RA (1998) Solid-phase synthesis of trisubstituted bicyclic guanidines via cyclization of reduced n-acylated dipeptides. J Org Chem 63:8622-8623
55. Harding WW, Tidgewell K, Byrd N, Cobb H, Dersch CM, Butelman ER, Rothman RB, Prisinzano TE (2005) Neoclerodane diterpenes as a novel scaffold for m opioid receptor ligands. J Med Chem 48:4765-4771
56. Prisinzano TE, Tidgewell K, Harding WW (2005) k Opioids as potential treatments for stimulant dependence. AAPS J 07:E592-E599
57. Tidgewell K, Groer CE, Harding WW, Lozama A, Schmidt M, Marquam A, Hiemstra J, Partilla JS, Dersch CM, Rothman RB, Bohn LM, Prisinzano TE (2008) Herkinorin analogues with differential b-arrestin-2 interactions. J Med Chem 51:2421-2431
58. Lin C-E, Takemori AE, Portoghese PS (1993) Synthesis and k-opioid antagonist selectivity of a norbinaltorphimine congener. Identification of the address moiety required for k-antagonist activity. J Med Chem 36:2412-2415
59. Jones RM, Hjorth SA, Schwartz TW, Portoghese PS (1998) Mutational evidence for a common k antagonist binding pocket in the wild-type k and mutant m[K303E] opioid receptors. J Med Chem 41:4911-4914
60. Metzger TG, Paterlini MG, Ferguson DM, Portoghese PS (2001) Investigation of the selectivity of oxymorphone- and naltrexone-derived ligands via site-directed mutagenesis of opioid receptors: exploring the 'address' recognition locus. J Med Chem 44:857-862
61. Martin WR (1983) Pharmacology of opioids. Pharmacol Rev 35:283-323
62. Feinberg AP, Creese I, Snyder SH (1976) The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists. Proc Natl Acad Sci USA 73:4215-4219
63. Portoghese PS (1965) A new concept on the mode of interaction of narcotic analgesics with receptors. J Med Chem 8:609-616
64. Portoghese PS, Alreja BD, Larson DL (1981) Allylprodine analogs as receptor probes. Evidence that phenolic and nonphenolic ligands interact with different subsites on identical opioid receptors. J Med Chem 24:782-787
65. Gozalbes R, Barbosa F, Nicolä? E, Horvath D, Froloff N (2009) Development and validation of a pharmacophore-based QSAR model for the prediction of CNS activity. ChemMedChem 4:204-209
66. Medina-Franco JL, Martnez-Mayorga K, Bender A, Marn RM, Giulianotti MA, Pinilla C, Houghten RA (2009) Characterization of activity landscapes using 2D and 3D similarity methods: consensus activity cliffs. J Chem Inf Model 49:477-491
67. Yamaotsu N, Fujii H, Nagase H, Hirono S (2010) Identification of the three-dimensional pharmacophore of κ-opioid receptor agonists. Bioorg Med Chem 18:4446-4452
68. Fujii H, Narita M, Mizoguchi H, Murachi M, Tanaka T, Kawai K, Tseng LF, Nagase H (2004) Drug design and synthesis of e opioid receptor agonist: 17-(cyclopropylmethyl)-4,5a-epoxy-3,6b-dihydroxy-6,14-endoethenomorphinan-7a-(N- methyl-N-phenethyl)carboxamide (TAN-821) inducing antinociception mediated by putative e opioid receptor. Bioorg Med Chem 12:4133-4145
69. Kuhl U, von Korff M, Baumann K, Burschka C, Holzgrabe U (2001) Stereochemical behaviour of k-agonistic 2,4-dipyridin-2-yl-3,7-diazabicyclo[3.3. 1]nonanones-influence of the substituent in position N3. J Chem Soc Perkin Trans 2:2037-2042
70. Tsujishita H, Hirono S (1997) Camdas: an automated conformational analysis system using molecular dynamics. J Comput Aided Mol Des 11:305-315
71. Halgren TA (1999) MMFF VI. MMFF94s option for energy minimization studies. J Comput Chem 20:720-729
72. Halgren TA (1999) MMFF VII. Characterization of MMFF94, MMFF94s, and other widely available force fields for conformational energies and for intermolecular-interaction energies and geometries. J Comput Chem 20:730-748
73. Iwase K, Hirono S (1999) Estimation of active conformations of drugs by a new molecular superposing procedure. J Comput Aided Mol Des 13:499-512
74. Nagase H, Osa Y, Nemoto T, Fujii H, Imai M, Nakamura T, Kanemasa T, Kato A, Gouda H, Hirono S (2009) Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett 19:2792-2795